The subject of crystal engineering
started in the 1970s with the
study of topochemical reactions in the solid state. A broad chemical
definition of crystal engineering was published in 1989, and the supramolecular
synthon concept was proposed in 1995 followed by heterosynthons and
their potential applications for the design of pharmaceutical cocrystals
in 2004. This review traces the development of supramolecular synthons
as robust and recurring hydrogen bond patterns for the design and
construction of supramolecular architectures, notably, pharmaceutical
cocrystals beginning in the early 2000s to the present time. The ability
of a cocrystal between an active pharmaceutical ingredient (API) and
a pharmaceutically acceptable coformer to systematically tune the
physicochemical properties of a drug (i.e., solubility, permeability,
hydration, color, compaction, tableting, bioavailability) without
changing its molecular structure is the hallmark of the pharmaceutical
cocrystals platform, as a bridge between drug discovery and pharmaceutical
development. With the design of cocrystals via heterosynthons and
prototype case studies to improve drug solubility in place (2000–2015),
the period between 2015 to the present time has witnessed the launch
of several salt–cocrystal drugs with improved efficacy and
high bioavailability. This review on the design, synthesis, and applications
of pharmaceutical cocrystals to afford improved drug products and
drug substances will interest researchers in crystal engineering,
supramolecular chemistry, medicinal chemistry, process development,
and pharmaceutical and materials sciences. The scale-up of drug cocrystals
and salts using continuous manufacturing technologies provides high-value
pharmaceuticals with economic and environmental benefits.